Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Shinnichi Ohkawa"'
Autor:
Takaki Yoshikawa, Soichiro Morinaga, Makoto Akaike, Akio Higuchi, Masahiro Asari, Manabu Shiozawa, Makoto Ueno, Yusuke Katayama, Manabu Morimoto, Shinnichi Ohkawa, Munetaka Masuda, Masaaki Murakawa, Naoto Yamamoto, Toru Aoyama, Satoshi Kobayashi, Amane Kanazawa, Yasushi Rino
Publikováno v:
Cancer Chemotherapy and Pharmacology. 74:1235-1240
The factors which affect the 6-month continuation of adjuvant chemotherapy with S-1 have not been fully evaluated in pancreatic cancer. The objective of this retrospective study was to clarify the risk factors for the discontinuation of S-1 adjuvant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eff35ac3c44cd24e7c2e0f1b51c1538
https://doi.org/10.1007/s00280-014-2601-y
https://doi.org/10.1007/s00280-014-2601-y
Autor:
Hiroshi Mikayama, Soichiro Morinaga, Yoshiyasu Nakamura, Manabu Shiozawa, Yohei Miyagi, Shinnichi Ohkawa, Hiroshi Tamagawa, Takuo Watanabe, Naoto Yamamoto, Yoichi Kameda, Makoto Akaike
Publikováno v:
Annals of surgical oncology. 19
Gemcitabine is a promising adjuvant treatment for patients with resected pancreatic cancer. Human equilibrative nucleoside transporter-1 (hENT1) is the major transporter responsible for gemcitabine uptake into cells. The aim of this study was to retr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52bce2b0efafa2b16d2d333db2f04ecb
https://pubmed.ncbi.nlm.nih.gov/21913012
https://pubmed.ncbi.nlm.nih.gov/21913012